KR102386481B1 - 알레르기 치료용 핵산 - Google Patents

알레르기 치료용 핵산 Download PDF

Info

Publication number
KR102386481B1
KR102386481B1 KR1020207012427A KR20207012427A KR102386481B1 KR 102386481 B1 KR102386481 B1 KR 102386481B1 KR 1020207012427 A KR1020207012427 A KR 1020207012427A KR 20207012427 A KR20207012427 A KR 20207012427A KR 102386481 B1 KR102386481 B1 KR 102386481B1
Authority
KR
South Korea
Prior art keywords
ser
gly
ala
leu
asn
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020207012427A
Other languages
English (en)
Korean (ko)
Other versions
KR20200047792A (ko
Inventor
윌리엄 헤알
테리 헤이랜드
Original Assignee
이뮤노믹 쎄라퓨틱스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 이뮤노믹 쎄라퓨틱스, 인크. filed Critical 이뮤노믹 쎄라퓨틱스, 인크.
Publication of KR20200047792A publication Critical patent/KR20200047792A/ko
Application granted granted Critical
Publication of KR102386481B1 publication Critical patent/KR102386481B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A61K39/36—Allergens from pollen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/34—Antigenic peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/06—Fusion polypeptide containing a localisation/targetting motif containing a lysosomal/endosomal localisation signal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Botany (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
KR1020207012427A 2012-06-15 2012-06-15 알레르기 치료용 핵산 Active KR102386481B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020157000696A KR102107646B1 (ko) 2012-06-15 2012-06-15 알레르기 치료용 핵산
PCT/US2012/042552 WO2013187906A1 (en) 2012-06-15 2012-06-15 Nucleic acids for treatment of allergies

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020157000696A Division KR102107646B1 (ko) 2012-06-15 2012-06-15 알레르기 치료용 핵산

Publications (2)

Publication Number Publication Date
KR20200047792A KR20200047792A (ko) 2020-05-07
KR102386481B1 true KR102386481B1 (ko) 2022-04-14

Family

ID=49758576

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020207012427A Active KR102386481B1 (ko) 2012-06-15 2012-06-15 알레르기 치료용 핵산
KR1020157000696A Active KR102107646B1 (ko) 2012-06-15 2012-06-15 알레르기 치료용 핵산

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020157000696A Active KR102107646B1 (ko) 2012-06-15 2012-06-15 알레르기 치료용 핵산

Country Status (20)

Country Link
US (3) US9744230B2 (https=)
EP (2) EP3808361A1 (https=)
JP (1) JP5807994B2 (https=)
KR (2) KR102386481B1 (https=)
CN (2) CN107937423A (https=)
AU (3) AU2012382406B2 (https=)
BR (1) BR112014031327B1 (https=)
CA (1) CA2876824C (https=)
CY (1) CY1123769T1 (https=)
DK (1) DK2861240T3 (https=)
ES (1) ES2831723T3 (https=)
HR (1) HRP20201815T1 (https=)
HU (1) HUE052481T2 (https=)
IL (4) IL236174B (https=)
LT (1) LT2861240T (https=)
PL (1) PL2861240T3 (https=)
PT (1) PT2861240T (https=)
RS (1) RS61098B1 (https=)
SI (1) SI2861240T1 (https=)
WO (1) WO2013187906A1 (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160185831A1 (en) * 2011-06-14 2016-06-30 Immunomic Therapeutics, Inc. Nucleic acids for treatment of allergies
AU2012382406B2 (en) * 2012-06-15 2017-12-07 Immunomic Therapeutics, Inc. Nucleic acids for treatment of allergies
PL2914286T3 (pl) 2012-10-30 2022-01-31 Aravax Pty Ltd Nowe cząsteczki immunoterapeutyczne oraz ich zastosowania
WO2015042664A1 (en) 2013-09-25 2015-04-02 Monash University Novel immunotherapeutic composition and uses thereof
WO2015200357A2 (en) * 2014-06-23 2015-12-30 Immunomic Therapeutics, Inc. Nucleic acids for treatment of peanut allergies
US10166286B2 (en) 2015-02-20 2019-01-01 The Board Of Trustees Of The Leland Stanford Junior University Mixed allergen compositions and methods for using the same
US10149904B2 (en) 2015-02-20 2018-12-11 The Board Of Trusteees Of The Leland Stanford Junior University Mixed allergen compositions and methods for using the same
US11452774B2 (en) 2015-02-20 2022-09-27 The Board Of Trustees Of The Leland Stanford Junior University Mixed allergen compositions and methods for using the same
US10143742B2 (en) 2015-02-20 2018-12-04 The Board Of Trustees Of The Leland Stanford Junior University Mixed allergen compositions and methods for using the same
TWI752930B (zh) 2015-12-23 2022-01-21 德商梅迪基因免疫治療公司 抗原特異性ｔｃｒ的新生成
US11826423B2 (en) 2016-11-16 2023-11-28 Immunomic Therapeutics, Inc. Nucleic acids for treatment of allergies
IL270024B2 (en) * 2017-04-22 2025-04-01 Immunomic Therapeutics Inc LAMP structures and their use in vaccination
KR20200016224A (ko) * 2017-05-02 2020-02-14 이뮤노믹 쎄라퓨틱스, 인크. 암 항원을 포함하는 lamp (리소솜 연관 막 단백질) 구축물
WO2019018529A1 (en) 2017-07-18 2019-01-24 Before Brands, Inc. METHODS OF MAKING MIXED ALLERGEN COMPOSITIONS
CN111936856A (zh) * 2018-04-06 2020-11-13 Sls生物有限公司 新型免疫球蛋白e的表位、与其结合的抗体及包括所述抗体的用于分析试料中免疫球蛋白e的试剂盒
US20210163957A1 (en) 2018-05-11 2021-06-03 Astellas Pharma Inc. Nucleic acid for treating mite allergy
JOP20200284A1 (ar) 2018-05-11 2020-11-09 Astellas Pharma Inc حمض نووي لعلاج حساسية القشريات
EP3793595A1 (en) 2018-05-15 2021-03-24 Immunomic Therapeutics, Inc. Improved lamp constructs comprising allergens
AU2020213085A1 (en) 2019-01-23 2021-08-12 Société des Produits Nestlé S.A. Methods for making mixed allergen compositions
EP3938053A4 (en) * 2019-03-13 2023-03-22 Psomagen, Inc. EPITOP-BASED APPROACH TO ALLERGY TREATMENTS AND INHIBITORS FOR CROHN'S DISEASE
US12150461B2 (en) * 2021-05-04 2024-11-26 Sovida Solutions Ltd. Nicotinamide adenine dinucleotide (NAD) compositions, methods of manufacturing thereof, and methods of use thereof
WO2023013785A1 (ja) * 2021-08-06 2023-02-09 花王株式会社 Ｓｎａｒｅを活用した核酸構築物
FI131854B1 (en) 2023-05-29 2026-01-12 Onni Biotechnologies Oy Modified natural killer cells with enhanced cytotoxic activity and greater survival

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002080851A3 (en) 2001-04-05 2003-02-27 Univ Johns Hopkins Chimeric vaccines

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USD335810S (en) 1990-07-02 1993-05-25 Dick-Ming Asien Handle for luggage or similar article
US6982326B1 (en) 1991-07-12 2006-01-03 Immulogic Pharmaceutical Corporation Allergenic proteins and peptides from Japanese cedar pollen
US6090386A (en) 1991-07-12 2000-07-18 Griffith; Irwin J. T cell peptides of the CRX JII allergen
WO1994024281A1 (en) * 1993-04-14 1994-10-27 Immulogic Pharmaceutical Corporation T cell epitopes of the major allergens from dermatophagoides (house dust mite)
CA2148713A1 (en) * 1992-11-12 1994-05-26 Mei-Chang Kuo Allergenic proteins and peptides from japanese cedar pollen
US5633234A (en) 1993-01-22 1997-05-27 The Johns Hopkins University Lysosomal targeting of immunogens
JP3649460B2 (ja) 1993-11-05 2005-05-18 明治乳業株式会社 スギ花粉アレルゲンＣｒｙ ｊ ＩＩエピトープ
GB9516760D0 (en) 1995-08-16 1995-10-18 Sandoz Ltd Organic compounds
EP0873135B1 (en) 1995-12-29 2009-07-22 The University of Arkansas Peanut allergens and methods
CN101307095A (zh) 1996-06-14 2008-11-19 明治乳业株式会社 T细胞表位肽
US20020142978A1 (en) * 2000-04-07 2002-10-03 Eyal Raz Synergistic improvements to polynucleotide vaccines
AU2002306850A1 (en) 2001-03-16 2002-10-03 Panacea Pharmaceuticals Methods and reagents for decreasing clinical reaction to allergy
US20060003148A1 (en) 2004-06-30 2006-01-05 Zwynenburg James L Interlocking polymeric foam floor underlayment and process for making
WO2006099574A2 (en) 2005-03-16 2006-09-21 Tai June Yoo Cockroach allergen gene expression and delivery systems and uses
WO2006138435A2 (en) 2005-06-16 2006-12-28 Mount Sinai School Of Medicine Methods for enhancing immune responses
US7566456B2 (en) 2005-06-23 2009-07-28 Haiming Chen Allergen vaccine proteins for the treatment and prevention of allergic diseases
JPWO2007024026A1 (ja) * 2005-08-25 2009-03-05 明石　満 Ｔ細胞認識エピトープペプチドを固定化又は内包化した生分解性ナノ粒子
US20080006554A1 (en) 2006-07-07 2008-01-10 Medtronic Vascular, Inc. Packaging assembly for a catheter
EP2042193A1 (en) * 2007-09-28 2009-04-01 Biomay AG RNA Vaccines
CN102186880A (zh) * 2008-09-10 2011-09-14 Ith免疫治疗控股股份公司 炎症的治疗
AU2012382406B2 (en) * 2012-06-15 2017-12-07 Immunomic Therapeutics, Inc. Nucleic acids for treatment of allergies
US11826423B2 (en) * 2016-11-16 2023-11-28 Immunomic Therapeutics, Inc. Nucleic acids for treatment of allergies
IL270024B2 (en) * 2017-04-22 2025-04-01 Immunomic Therapeutics Inc LAMP structures and their use in vaccination

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002080851A3 (en) 2001-04-05 2003-02-27 Univ Johns Hopkins Chimeric vaccines

Also Published As

Publication number Publication date
BR112014031327B1 (pt) 2022-02-01
CN107937423A (zh) 2018-04-20
AU2019250227A1 (en) 2019-11-07
JP2015521467A (ja) 2015-07-30
WO2013187906A1 (en) 2013-12-19
IL270261B (en) 2021-03-25
US9744230B2 (en) 2017-08-29
ES2831723T3 (es) 2021-06-09
HRP20201815T1 (hr) 2021-02-19
DK2861240T3 (da) 2020-09-28
CA2876824C (en) 2020-07-21
IL270262A (en) 2019-12-31
RS61098B1 (sr) 2020-12-31
SI2861240T1 (sl) 2021-04-30
KR20200047792A (ko) 2020-05-07
IL236174A0 (en) 2015-01-29
CA2876824A1 (en) 2013-12-19
PL2861240T3 (pl) 2021-07-05
AU2012382406B2 (en) 2017-12-07
BR112014031327A2 (pt) 2017-06-27
PT2861240T (pt) 2020-11-09
AU2019250227B2 (en) 2021-10-21
KR102107646B1 (ko) 2020-05-08
US20220081474A1 (en) 2022-03-17
AU2012382406A2 (en) 2015-04-16
IL270260B (en) 2020-08-31
EP2861240A4 (en) 2016-03-16
JP5807994B2 (ja) 2015-11-10
EP2861240B1 (en) 2020-09-09
KR20150032286A (ko) 2015-03-25
EP3808361A1 (en) 2021-04-21
HUE052481T2 (hu) 2021-04-28
CN104519896B (zh) 2017-11-10
IL236174B (en) 2019-11-28
US20180009857A1 (en) 2018-01-11
LT2861240T (lt) 2021-01-25
AU2018200625B2 (en) 2019-09-19
CN104519896A (zh) 2015-04-15
AU2012382406A1 (en) 2014-12-18
AU2018200625A1 (en) 2018-02-15
EP2861240A1 (en) 2015-04-22
US10072053B2 (en) 2018-09-11
CY1123769T1 (el) 2022-05-27
US20160271245A1 (en) 2016-09-22

Similar Documents

Publication Publication Date Title
KR102386481B1 (ko) 알레르기 치료용 핵산
RU2761631C2 (ru) Белки rsv в предшествующей слиянию конформации и их применение
JP5399895B2 (ja) ワクチン担体
Pownall et al. Safety of a novel Listeria monocytogenes-based vaccine vector expressing NcSAG1 (Neospora caninum surface antigen 1)
US20160185831A1 (en) Nucleic acids for treatment of allergies
Doan et al. Immunization-induced antigen archiving enhances local memory CD8+ T cell responses following an unrelated viral infection
US20230310585A1 (en) Vaccine for viral pathogens
CN115715198A (zh) 新型的基于沙门氏菌的冠状病毒疫苗
HK1253363A1 (zh) 用於治疗变态反应的核酸
WO2017024084A1 (en) Immunogenic compositions, antigen screening methods, and methods of generating immune responses
JP6353510B2 (ja) アレルギー治療のための核酸
KR20210007977A (ko) 진드기 알레르기 치료를 위한 핵산
Tamburini et al. Vaccine-induced antigen archiving enhances local memory CD8+ T cell responses following an unrelated viral infection
Yanik et al. Immature dendritic cell-targeting mRNA vaccine expressing PfCSP enhances protective immune responses against Plasmodium liver infection

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 4